AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
BioPharma Dive
Featured at this year s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
pharminent
April 20, 2026 (Last updated: April 20, 2026)
BioPharma Dive
Featured at this year s meeting on early cancer research were results from an immunotherapy Merck acquired in 2024 and several targeted medicines for lung tumors.
